SOCRA | Clinical Trials on Alzheimer’s Disease: Challenges and Opportunities [Video]

About this event

Clinical trials targeting Alzheimer’s disease face multifaceted challenges amidst promising opportunities. Challenges include patient recruitment, high attrition rates, and complex trial designs. Additionally, the disease’s heterogeneous nature poses diagnostic and treatment challenges. However, advancements in biomarkers, precision medicine, and collaborative research efforts offer opportunities for innovative trial designs and targeted therapies. Addressing these challenges while leveraging emerging opportunities is crucial for advancing Alzheimer’s disease clinical research and developing effective treatments for this devastating condition.

Discussion Lead

Dr. Benedict C. Albensi, Ph.D., BCMAS, CRQM.

– Principal Investigator, Synaptic Plasticity and Cellular Memory Dysfunction Lab, Division of Neurodegenerative Disorders St. Boniface Hospital Albrechtsen Research Centre
– Professor (External Adjunct) Department of Pharmacology & Therapeutics, College of Medicine, Faculty of Health Sciences
– Former Manitoba Dementia Research Chair
– Former Everett Endowment Fund Chair
– Currently Dr. Benedict C. Albensi is a Professor and Chair of the Department of Pharmaceutical Sciences at Nova Southeastern University, Ft. Lauderdale, Florida

Biography
Dr. Benedict C. Albensi is a Professor and Chair of the Department of Pharmaceutical Sciences at Nova Southeastern University, Ft. Lauderdale, Florida. Additionally, he holds a Professorship of Pharmacology and Therapeutics at the Max Rady College of Medicine, University of Manitoba. Dr. Albensi serves as the Everett Endowment Fund Chair for Alzheimer’s Research at St. Boniface Hospital Research Centre. With a Ph.D. in Neuroscience from the University of Utah’s Medical School, his pioneering research focuses on ageing, cognition, and Alzheimer’s disease. Renowned for his insights into mitochondrial dysfunction in Alzheimer Disease, he ranks in the top 1% globally for neurodegenerative publications.